Calquence in combination with bendamustine and rituximab has been recommended for approval in the European Union, EU, for ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

AstraZeneca announced on Monday that it secured a US regulatory approval and a positive EU recommendation for two of its ...

FDA approved AstraZeneca's Imfinzi regimen for muscle-invasive bladder cancer, while the EU backed Calquence combo for untreated mantle cell lymphoma.

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib ...

The recommendation, announced today, is based on the ECHO Phase III trial results, which showed a notable improvement in progression-free survival when Calquence was used in combination with ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...

Calquence plus Venclexta, with or without Gazyva, significantly improved progression-free and overall survival in untreated CLL patients compared to chemoimmunotherapy. The study showed a higher ...

In particular, the company's launched cancer drugs Tagrisso, Imfinzi, Lynparza, and Calquence are well positioned based on leading efficacy in hard-to-treat cancers. These drugs also carry strong ...